Table II.
Characteristic | Asia, Europe and South/Central America | North America | ||||||
---|---|---|---|---|---|---|---|---|
Total (N = 2500) | HPV16/18 positive (N = 233, 9.3%) | HPV16/18 negative (N = 2267, 90.7%) | P valuea | Total (N = 663) | HPV16/18 positive (N = 23, 3.5%) | HPV16/18 negative (N = 640, 96.5%) | P valuea | |
Gender | 0.157 | 0.632 | ||||||
Male | 1749 (71.92) | 154 (66.96) | 1595 (72.43) | 349 (52.64) | 10 (43.48) | 339 (52.97) | ||
Female | 683 (28.08) | 76 (33.04) | 607 (27.57) | 314 (47.36) | 13 (56.52) | 301 (47.03) | ||
Age (years) | 0.529 | 0.557 | ||||||
≤66 | 1212 (51.33) | 92 (42.4) | 1120 (52.24) | 315 (47.51) | 10 (43.48) | 305 (47.66) | ||
>66 | 1149 (48.67) | 125 (57.6) | 1024 (47.76) | 348 (52.49) | 13 (56.52) | 335 (52.34) | ||
Race | 0.059 | 0.102 | ||||||
White | 1083 (43.32) | 27 (11.59) | 1056 (46.58) | 239 (88.52) | 13 (72.22) | 226 (89.68) | ||
Othersb | 1417 (56.68) | 206 (88.41) | 1211 (53.42) | 31 (11.48) | 5 (27.78) | 26 (10.32) | ||
Smoking history | 0.762 | 0.256 | ||||||
Never smoked | 602 (24.06) | 67 (28.93) | 534 (23.56) | 104 (15.69) | 3 (13.04) | 101 (15.78) | ||
Ever smoked | 1898 (75.94) | 166 (71.07) | 1733 (76.44) | 559 (84.31) | 20 (86.96) | 539 (84.22) | ||
Histology | 0.536 | 0.345 | ||||||
SCC | 953 (38.12) | 107 (45.92) | 846 (37.32) | 239 (36.43) | 5 (22.73) | 234 (36.91) | ||
Othersc | 1547 (61.88) | 126 (54.08) | 1421 (62.68) | 417 (63.57) | 17 (77.27) | 400 (63.09) | ||
Stage | 0.614 | 0.099 | ||||||
0/Id | 1240 (49.60) | 108 (46.52) | 1132 (49.92) | 422 (63.63) | 15 (65.65) | 407 (63.59) | ||
II | 460 (18.41) | 36 (15.41) | 424 (18.72) | 106 (16.01) | 1 (5.59) | 105 (16.39) | ||
III | 479 (19.14) | 43 (18.37) | 436 (19.22) | 109 (16.43) | 3 (13.91) | 106 (16.53) | ||
IV | 321 (12.84) | 46 (19.70) | 275 (12.14) | 26 (3.93) | 4 (16.52) | 22 (3.48) |
Data are presented as number of patients (%).
a P value was calculated by a logistic regression model with study as a random effect.
bOthers include Black, Hispanic, Asian and race not specified.
cOthers include adenocarcinoma and histology not specified.
dIncludes four cases with stage 0 (in situ).